检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:霍树芬[1] 尚文丽[1] 田应选[1] 孙莉[1] 任小平[1] 王君[1] 康慧芳 温红侠[1] HUO Shu-fen;SHANG Wen-li;TIAN Ying-xuan;SUN Li;REN Xiao-ping;WANG Jun;KANG Hui-fang;WEN Hong-xia(Department of Respiratory and Critical Care, Shaanxi Provincial People′s Hospital, Xi′an 710068, China)
机构地区:[1]陕西省人民医院呼吸与危重症二科,陕西省西安市710068
出 处:《实用老年医学》2022年第5期473-477,共5页Practical Geriatrics
基 金:陕西省科技厅重点研发计划(2019SF-185);西安市科技局“科技+”行动计划--医学研究项目[201805093YX1SF27(9)];科技部主动健康和老龄化科技应对国家重点研发计划课题(2018YFC2002100,2018YFC2002103)。
摘 要:目的探讨程序性细胞死亡受体1/程序性细胞死亡配体1(PD-1/PD-L1)抑制剂治疗对老年非小细胞肺癌(NSCLC)合并COPD病人气道高反应和肺功能的影响。方法纳入30例接受PD-1/PD-L1抑制剂免疫治疗的NSCLC病人,分为合并COPD组和未合并COPD组,收集治疗前后呼出气一氧化氮(FeNO)和肺功能指标,并进行统计学分析。结果30例病人中19例合并COPD,11例未合并COPD。治疗前,2组FeNO水平差异无统计学意义(P>0.05);治疗后,COPD组FeNO水平较治疗前显著升高,且明显高于非COPD组,差异均有统计学意义(P<0.01)。COPD组治疗后FEV1、FVC水平较治疗前均明显升高(P<0.05)。非COPD组治疗前后FVC和FEV1水平比较,差异无统计学意义(P>0.05)。2组治疗前后改良呼吸困难指数(mMRC)问卷评分或COPD评估测试(CAT)评分差异均无统计学意义(P>0.05),治疗期间无COPD急性加重发生。结论PD-1/PD-L1抑制剂免疫治疗可改变NSCLC合并COPD病人的FeNO水平和肺功能,且不会使COPD恶化。Objective To investigate the effects of programmed death-1(PD-1)/programmed death-ligand 1(PD-L1)inhibitor treatment on airway hyperresponsiveness and lung function in the elderly patients with non-small cell lung cancer(NSCLC)complicated with chronic obstructive pulmonary disease(COPD).Methods A total of 30 NSCLC patients who received PD-1/PD-L1 inhibitor immunotherapy were divided into COPD group and non-COPD group.The levels of fractional exhaled nitric oxide(FeNO)and the lung function indexes were collected and compared.Results Among the 30 patients,19 cases were complicated with COPD and 11 cases were not complicated with COPD.There was no statistical difference in the level of FeNO between the COPD group and the non-COPD group before treatment(P>0.05).The level of FeNO was increased significantly in the COPD group affter treatment,and the difference between the two groups was statistically significant(P<0.01).After treatment,the levels of FEV1 and FVC were increased significantly in the COPD group(P<0.05).However,there was no statistically significant difference in FVC and FEV1 before and after treatment in the non-COPD group(P>0.05).There were no significant differences in scores of Modified Medical Research Conncil(mMRC)questionnaire and COPD Assessment Test(CAT)between the two groups before and after treatment(P>0.05).Acute exacerbation of chronic obstructive pulmonary disease(AECOPD)was not observed during treatment.Conclusions PD-1/PD-L1 inhibitor immunotherapy can change FeNO level and pulmonary function in the NSCLC patients with COPD,and will not worsen COPD.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.28